Press Releases
Site - Investor Relations
Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development
First is Predictive Oncology’s Good Manufacturing Practices (GMP) lab, which opens the opportunity to help clients move from pre-clinical drug development to the investigational new drug (IND) qualification, including phase 1 clinical trials. The company has begun accepting orders.
“Adding GMP production capabilities at
Second,
A proven leader in the biopharmaceutical industry,
“Dr. Egodage brings an in-depth knowledge of the biopharmaceutical regulatory and development process that makes him an ideal fit for the growth plans we have at
Dr. Egodage’s engagement comes at a time of growth for
- Today,
Predictive Oncology announces the next generation of a classical static light scattering (SLS) instrument that will be the first of its kind. The Free Flow SLS instrument is a rapid automated static light scattering system that will expand the company’s offerings with additional throughput capabilities in developing formulations for customers with proteins, peptides, vaccines and whole attenuated virus vaccines. - The company also is introducing a new high-capacity endotoxin column, called EndoBind-R II, which more effectively removes endotoxins from aqueous samples. This is a non-epoxy media with a high concentration of peptide bound that can be operated under HPLC (high-pressure) conditions to reduce endotoxin levels below required FDA levels.
Inquiries for the new products or GMP lab capabilities can be made by emailing
About
About Canopy Biopharma
Public Relations Contact:
630-566-2003
tferguson@predictive-oncology.com
Investor Relations Contact:
(404) 995-6671
kpinder@landoncapital.net
Forward-Looking Statements:
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects for new and existing products and in general, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.
Source: Predictive Oncology Inc.